A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2018
Price : $35 *
At a glance
- Drugs Azacitidine (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2018 Planned number of patients changed from 20 to 25.
- 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.